These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7903917)

  • 41. Review of amsacrine, an investigational antineoplastic agent.
    Grove WR; Fortner CL; Wiernik PH
    Clin Pharm; 1982; 1(4):320-6. PubMed ID: 6764391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia.
    Tetreault SA; Saven A
    Leuk Lymphoma; 2000 Mar; 37(1-2):125-30. PubMed ID: 10721776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies.
    Saven A; Piro LD
    Ann Intern Med; 1994 May; 120(9):784-91. PubMed ID: 7908507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2-chloro-2'-deoxyadenosine: clinical applications in hematology.
    Delannoy A
    Blood Rev; 1996 Sep; 10(3):148-66. PubMed ID: 8932828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.
    Guchelaar HJ; Richel DJ; Schaafsma MR
    Ann Hematol; 1994 Nov; 69(5):223-30. PubMed ID: 7948311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biotherapy in clinical practice.
    Figlin RA
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cladribine conundrum: deciphering the drug's mechanism of action.
    Hentosh P; Peffley DM
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):75-81. PubMed ID: 19968576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternative methods of cladribine administration.
    Lauria F; Cencini E; Forconi F
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():34-7. PubMed ID: 21504286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides.
    Satishkumar S; Vuram PK; Relangi SS; Gurram V; Zhou H; Kreitman RJ; Martínez Montemayor MM; Yang L; Kaliyaperumal M; Sharma S; Pottabathini N; Lakshman MK
    Molecules; 2015 Oct; 20(10):18437-63. PubMed ID: 26473811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [2-chlorodeoxyadenosine (2-CDA)--a new antineoplastic and immunosuppressive drug].
    Robak T; Grieb P
    Acta Haematol Pol; 1992; 23(3):141-8. PubMed ID: 1362851
    [No Abstract]   [Full Text] [Related]  

  • 51. Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review.
    Verma V; Giri S; Bhatt VR; Amador-Ortiz C; Armitage JO
    Front Oncol; 2016; 6():270. PubMed ID: 28119853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New analogs of deoxyadenosine for treatment of lymphoid malignancies].
    Robak T
    Przegl Lek; 1992; 49(10):355-8. PubMed ID: 1364050
    [No Abstract]   [Full Text] [Related]  

  • 53. 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
    Saven A; Piro LD
    Leuk Lymphoma; 1993; 10 Suppl():43-9. PubMed ID: 8097654
    [No Abstract]   [Full Text] [Related]  

  • 54. Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy.
    Jain A; Lad D; Prakash G; Khadwal A; Malhotra P; Bal A; Mallik N; Kumar N; Varma S
    Indian J Hematol Blood Transfus; 2017 Jun; 33(2):273-275. PubMed ID: 28596664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Use of 2-chloro-2'-deoxyadenosine (2-CdA) in therapy of hematologic diseases].
    Komarnicki M; Rasińska M
    Pol Arch Med Wewn; 1993 Jul; 90(1):68-71. PubMed ID: 7901843
    [No Abstract]   [Full Text] [Related]  

  • 56. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.
    Santana VM; Hurwitz CA; Blakley RL; Crom WR; Luo X; Roberts WM; Ribeiro R; Mahmoud H; Krance RA
    Blood; 1994 Aug; 84(4):1237-42. PubMed ID: 7914104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical pharmacokinetics of cladribine.
    Liliemark J
    Clin Pharmacokinet; 1997 Feb; 32(2):120-31. PubMed ID: 9068927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro response of human pathological hematopoietic cells to cladribine.
    Mazur L; Opydo-Chanek M; Stojak M; Janota B; Blicharski K; Wojcieszek K; Kłaput U; Borowicz P
    Folia Biol (Krakow); 2013; 61(3-4):143-8. PubMed ID: 24279161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association.
    Valvano L; D'Auria F; Grieco V; Statuto T; Nozza F; Pietrantuono G; Villani O; D'Arena G; Lamorte D
    Front Oncol; 2022; 12():1069977. PubMed ID: 36544707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Marrow suppression produced by repeated doses of cladribine.
    Beutler E; Koziol JA; McMillan R; Sipe JC; Romine JS; Carrera CJ
    Acta Haematol; 1994; 91(1):10-5. PubMed ID: 8171930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.